Source: European Parliament
The Commission would like to stress that the European Medicines Agency (EMA) cyberattack in 2020 was successfully contained without affecting the evaluation and approval of COVID-19 vaccines and therapeutics.
The EMA swiftly launched a full investigation, in close cooperation with the Dutch police, the Cybersecurity Service for the Union institutions, bodies, offices and agencies (CERT-EU) and Europol, the EU agency for law enforcement cooperation. The law enforcement investigation did not confirm the identities of the suspects involved in this criminal attack.
The EMA remains vigilant and has subsequently further strengthened its defensive cybersecurity capabilities to be better prepared for cyberattacks.
The EMA has also published a wealth of information about the evaluation of COVID-19 vaccines, including the clinical data submitted for assessment and the detailed assessment reports. The cyberattack did not impact the integrity of the data that were assessed by the EMA.
The Commission and the EMA would like to stress the importance of consulting reliable information sources and refer the public to the documents published on the EMA website.
The EMA will continue releasing documents to the public in line with its legal obligations and its transparency policy.